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ABSTRACT 
In this research we aimed to investigate the anti-proliferative properties of three South African 
plants: Kedrostis foetidissima, Euphorbia mauritanica and Elytropappus rhinocerotis against 
breast cancer cells. This was done on the basis of their documented ethno-medicinal use against 
cancer and other ailments. The plant extracts were screened for cytotoxicity and pro-apoptotic 
activity against two breast cancer cell lines MCF-7 and YMB-1. With an IC50 ~ 100 µg/ml, K. 
foetidissima was the only extract that exhibited significant cytotoxicity on both cell lines, whilst 
E. mauritanica was cytotoxic to MCF-7 cells only. The cytotoxicity assay was followed by the 
Annexin-V detection assay to evaluate the occurrence of apoptosis. The results observed 
suggested that K. foetidissima was inducing significant apoptosis on both YMB-1 and MCF-7 
cells, whilst E. mauritanica was inducing significant apoptosis on MCF-7 cells. 
Since both K. foetidissima and E. mauritanica crude extracts induced apoptosis to MCF-7 cells, 
they were selected for gene expression studies on MCF-7 using real-time PCR. This was done 
with the aim of investigating if these extracts were having an effect on the tumour suppressors 
p53 and RBBP6, which were shown in previous studies to be deregulated in up to 50% of 
cancers. From the real-time PCR data we observed no changes in the expression levels of these 
genes following treatment with the herbal extracts. This may suggest that these plants have an 
effect on other components of the apoptotic pathway other than the tumour suppressors p53 and 
RBBP6.  
The antiproliferative activity observed whilst treating these particular cell lines with K. 
foetidissima and E. mauritanica suggests that these South African herbal plants present 
vii 
 
themselves as potential future cancer therapeutic agents; however, further studies on these herbal 
plants need to be performed to validate these results. 
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CHAPTER 1 INTRODUCTION AND LITERATURE REVIEW 
1.1 Traditional medicine 
For generations, mankind has believed and still believes in the healing powers of plants, using 
them as medicine to treat various common infectious diseases. Some of these plants have been 
used for centuries and are still used even today as a primary source of healthcare. In spite of the 
increasing usage of modern medicines in some areas, there are still countries that don’t have 
regular access to essential drugs. The use of traditional plants as a great source of medicine has 
been greatly documented in African countries and other developing countries such as India and 
China. According to the World Health Organisation (WHO), 70-80% of the world’s population 
use herbal sources as medicine (Chan 2003).  
It is only in the 20
th
 century that there has been increasing interest in the use of natural resources, 
especially herbal medicine, as an alternative to orthodox medicine in industrialized countries. 
This has thus increased interest from pharmaceuticals, and phytotherapeutic research. Scientists 
started developing an interest in medicinal plants due to their documented antibacterial, 
antifungal, antiviral and even anti-amoebic properties (McGaw et al. 2000). Today, up to 50% of 
the world drugs are made from natural products or their derivatives (Gurib-Fakim 2006). Some 
of these drugs include aspirin, quinine and morphine amongst others (Singh and Barrett 2006). 
The recent surge in natural plants research has also led to production of drugs such as taxol, 
camptothecin and podofilox which are now being used for chemotherapy. These drugs were 
derived from parts of various plants (Itokawa et al. 2008; Pezzuto 1997). This has been a 
remarkable progress in elucidating the possible anti-apoptotic properties of plants. As researchers 
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worldwide continue to explore plants for their anti-cancer properties, breast cancer should also 
be at the forefront of medicinal plant research, since it is now the leading cause of cancer in 
females.  
1.2 Breast cancer 
1.2.1 Statistics 
Breast cancer is a malignant tumour that starts in the breast tissue; it usually starts in the ducts or 
in lobules. It can occur in both males and females; however, male breast cancer is rare. It is the 
second leading cancer in the world following lung cancer, with an estimated 1.15 million cases a 
year in 2002 (Parkin et al. 2005). The American Cancer Society estimated 182 460 cases (which 
accounted for 26% of all new cancer cases) for 2008 in the U.S.A alone, resulting in 40 480 
deaths (Jemal et al. 2008). Breast cancer is primarily a postmenopausal women’s disease, with 
the American National Cancer Institute’s Cancer Review estimating the average age of women at 
risk to be 61 years of age. Approximately 0 cases have being reported for women below 20, but 
the figures are gradually increasing with every decade (Altekruse et al. 2009). 
 In South Africa, between 1986 and 1992, cervical cancer was the most leading cause of cancer 
amongst women, but recently breast cancer seems to have overtaken and is now the most 
common cancer in females (Vorobiof et al. 2001; Siegel et al. 2011). Compared to the rest of the 
world, breast cancer cases are relatively low in Africa, with an estimated 65 000 new cases being 
reported in 2002. The highest incidence was observed in South Africa with about 6474 (or 35 per 
10
5
) cases being reported (Parkin et al. 2008). 
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1.2.2 Epidemiology 
The lifetime risk of an individual developing breast cancer cannot be attributed to one factor 
alone. A number of variables play a role in the development of breast malignancies. Even though 
it is fairly difficult to pinpoint one cause as the main risk factor for breast cancer, studies have 
shown there are certain genetic, reproductive and lifestyle factors that play a major role in its 
induction and progression. One of these factors is age, with studies finding that the incidence 
rates double with every 10 years up until menopause, where the rates start to dramatically decline 
(McPherson et al. 2000).  Exposure to radiation and use of oral contraceptives may be associated 
with induction of breast cancer (Ronckers et al. 2005; Urban et al. 2012).  
Very small fraction of breast cancers could be attributed to preventable lifestyle behaviour such 
as obesity, alcohol consumption, lack of physical activity and long term use of hormone 
replacement therapy. In several studies conducted to determine the role these factors have on 
breast cancer incidence, the data appears to be inconsistent, hence it is hard to establish the 
severity these factors play in breast cancer induction that is if they even do at all  (Chen et al. 
2006; Lorincz and Sukumar 2006; Zhang et al. 2007). In developed countries, incidence rates are 
higher relative to developing countries. However, incidence rates are steadily increasing in 
developing countries (Key et al. 2001). This increase may be attributed to the adoption of a more 
westernized lifestyle which encompasses a more sedentary lifestyle, delayed childbearing, high 
alcohol use and a diet high in fat (Bray et al. 2004; Porter 2008).  
In a lot of breast malignancies, hormones play a major role. It is known that estrogen starts breast 
tissue proliferation, and studies have now shown that the longer a woman is exposed to estrogen, 
the greater the risk of developing breast cancer. Hence, women with an early age at menarche 
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(<12 years), were found to be 2.2 times more likely to develop breast cancer in the future than 
those with late menarche (Peeters et al. 1994). In a different study, women who started 
menopause late i.e. at the age of 55, were found to have 44% higher breast cancer incidence rates 
than women who started menopause at 45. This may be due to a 10 year increase in the amount 
of estrogen the women are exposed to. Exposure to excessive exogenous estrogen plays a role in 
hyperestrogenia. Hyperestrogenia could trigger breast cancer in two ways: either by breast 
epithelium tumour promotion or by DNA damage which could be caused by estrogen 
metabolites directly (Butler et al. 2000; Imyanitov and Hanson 2004). 
Another important factor which may increase susceptibility to breast cancer is inheritance of 
susceptibility genes, it has been estimated that 7-10% of breast cancers arise due to inherited 
mutated genes. The major predisposing factors to breast cancer are breast susceptibility genes, 
known as BRCA1 and BRCA 2, which are important for early onset of breast cancer (Hedau et 
al. 2004; Imyanitov and Hanson 2004). An initial germline mutation in one of these genes 
followed by a second mutation leading to the loss of function of the second allele is required for 
induction of tumouriginesis (Powell and Kachnic 2003). These genetic factors mostly show an 
autosomal dominant pattern of inheritance, with germline mutations rendering susceptibility to 
the following generation (Loubser et al. 2008; Ponzone and Baum 1998). 
1.3 BRCA 1 and 2 
The BRCA genes are thought to be tumour suppressors since the wild type allele is often lost in 
tumours of heterozygous people (Tutt and Ashworth 2002).  It has been suggested that BRCA 1 
and BRCA2 genes play a role in a common pathway which controls DNA damage repair and 
DNA replication fidelity (Powell and Kachnic 2003). They are thought to be involved in repair 
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of damaged DNA associated with replication by homologous recombination. This they do by 
interacting with a recombinational repair protein Rad51, thereby maintaining genomic integrity 
(Tutt and Ashworth 2002; Welsch and King 2001). In accordance with their role in DNA repair; 
a cell with a mutant BRCA gene will not be able to have a functional protein product thereby 
leading to defects in DNA repair mechanisms.  It has been speculated that germline mutations in 
cancer susceptibility genes BRCA1 and BRCA2 led to an increased risk of developing breast 
cancer.  
Breast cancer patients with mutant BRCA 1 were found to contain up to 2 to 3 fold more 
chromosomal rearrangements than sporadic cancers (Thangaraju 2000). Abnormalities that arise 
due to mutant BRCA2 include broken chromosomes and chromatids as well as formation of 
abnormal structures which mark an abnormal mitotic recombination which has been linked to 
predisposition to diseases such as Blooms syndrome and also leaves the person with high 
susceptibility to various types of cancers (Venkitaraman 2002). Ford et al. (1998) showed that 
up to 84% of hereditary breast cancers were linked to mutations in either BRCA1 or BRCA2 
whilst only 16% of breast cancer cases were not linked to BRCA mutations. 
BRCA1 tumour suppressor gene encodes an 1863-amino acid and is located at 17q21. BRCA1 is 
implicated in many cellular pathways including transcription, cell cycle, checkpoint control, 
apoptosis and DNA repair (Venkitaraman 2002). BRCA2 is a breast cancer susceptibility gene 
located at 13q12-q13 which the product is thought to be involved in monitoring genome integrity 
and cell cycle progression. BRCA 2-null mice have been reported to have a defect in embryonic 
cellular proliferation and die in the uterus (Cheung et al. 2002). 
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Though BRCA mutations have been implicated in a lot of breast cancer cases, there are still 
breast cancers which occur due to deregulation of other genes. A substantial proportion of 
susceptibility to breast cancer can be attributed to mutations in cell cycle regulation and 
apoptosis genes. 
1.4 Cell cycle 
The cell cycle is an important regulator of DNA replication, cell growth and cell division 
(Schwartz and Shah 2005). It entails a series of highly coordinated steps, these are divided into 4 
distinct stages: G1-phase - gap phase, it represents the stage of entry into the cell cycle whereby 
cells prepare for the S-phase; S-phase- DNA synthesis; G2- the second gap phase, a period of 
rapid cell growth where cells prepare for mitosis and M phase which represents mitosis, which 
entails cell division resulting in the formation of 2 daughter cells from each cell (Caldon et al. 
2006; Schwartz and Shah 2005). It is essential for a cell to complete one phase before 
proceeding to another to ensure orderly transitions.  
One of the most important things is for cells to ensure repair of damaged DNA and prevention of 
uncontrolled proliferation whilst going through the cell cycle. The most important mechanisms 
that mammalian cells have developed to deal with constant DNA damage is the development of 
cell cycle control checkpoints. This is a mechanism in which cell progression through the cell 
cycle is arrested, to prevent cells with damaged DNA from undergoing DNA replication or 
mitosis and this is mainly mediated by cyclin-dependent kinases (CDKs) (Kastan and Bartek 
2004; Malumbres and Barbacid  2005). CDKs require specific regulatory proteins known as 
cyclins to be positively regulated and they are negatively regulated by CDK inhibitors (Schwartz 
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and Shah 2005). Depending on which stage of the cell cycle the cell is in will be the determining 
factor on which particular CDK will be expressed by its respective cyclin.  
During the G1 phase, a signal will induce synthesis of D-cyclins which will interact with 
CDK4/6, these will form complexes and phosphorylate the tumour suppressor retinoblastoma 
(Rb) (Malumbres and Barbacid 2005; Potten and Wilson 2004). To bring about G1 cell cycle 
arrest, Rb protein interacts with E2F family of transcription factors (Weinberg 1995). 
Association between CDK2 and cyclin E drives the cell to the S-phase. Cyclin A’s interaction 
with CDK2 will drive the cell through the S-phase. Whilst the cyclin A-CDK1 and cyclin B-
CDK1 will get the cells through the S-phase to mitosis transition (Schwartz and Shah 2005) (see 
Figure 1.1). The two most important checkpoints being the G1 and the G2 checkpoints, the G1 
checkpoint ensures that cells with a damaged DNA do not undergo DNA replication and the G2 
checkpoint that unreplicated and damaged DNA do not undergo mitosis. 
There has been increasing evidence that implicates cell cycle control disruption as a common 
pathway in the development of breast tumouriginesis. The fidelity of the cell cycle requires a 
coordinated complex between DNA repair, metabolic adjustments, cell death, chromatin 
remodeling which are controlled by regulatory surveillance systems (Elledge 1996). Mutations 
in genes involved in DNA damage responses and mitotic checkpoints pathways, may allow 
continued proliferation of genes with aberrant DNA, thus leading to increased chances of cancer 
(Kastan and Bartek 2004). The two most important genes that control the cell cycle that have 
been implicated in tumouriginesis being the tumour suppressors p53 and pRb, and these will be 
discussed further in the following section.  
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Figure 1.1: Schematic representation of cell cycle regulation indicating G1, S and G2 
checkpoints.  
The phase specific cyclin-dependent kinases (CDKs) and their regulatory proteins known as 
cyclins are shown. The negative regulators of the CDKs are p16, p21 and p27. The tumour 
suppressor protein pRb in its phosphorylated form is required for progression through the G1 
phase whilst p53 is essential for both the G1 and G2 checkpoints (Stewart et al. 2001).  
1.5 Apoptosis 
Apoptosis is a fundamental process that occurs throughout the lives of most organisms, from 
humans to simple organisms such as hydra, to insects, amphibian and fish (Potten and Wilson 
2004). It is an active form of programmed cell death which is important for maintaining 
p16/p21/p27 
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homeostasis by ensuring a balance between proliferation of normal cells and non-inflammatory 
death of damaged cells in adult multicellular organisms (Kerr et al. 1972). Deregulation of 
apoptosis could lead to induction of certain human disease including neurodegenerative 
disorders such as Alzheimer’s and Parkinson’s diseases, autoimmune disorders e.g., multiple 
sclerosis and rheumathoid arthritis and various types of cancers (Fadeel et al. 1999). It also plays 
a crucial role in embryonic development (Kerr et al. 1972). It is important for mammalian 
development and patterning of structures such as organs (brains, eyes) and limbs. Failure of 
apoptosis regulation could lead to an observable phenotype characterized by various defects 
(Lang 1997; Haydar et al. 1999; Potten and Wilson 2004).  
Even though apoptosis may be triggered by various stimuli, it is initiated by two major pathways 
the intrinsic and the extrinsic pathways (Boatright and Salvesen 2003).  
(i) Intrinsic pathway  
The intrinsic pathway is regulated by pro- and anti-apoptotic members of the Bcl-2 family, 
which will either induce or prevent permeabilization of the outer mitochondrial membrane. Once 
an apoptotic signal is received, it will lead to activities of signal inducing pro-apoptotic members 
of the Bcl-2 family leading to permeabilization of the outer mitochondrial membrane (Green and 
Kroemer 2004).  This will lead to release of cytochrome c into the cell cytoplasm, which had 
been sequestered in the mitochondrial intermembrane space (Schuler et al. 2000).  Cytochrome c 
will then bind to the protein apoptosis-protease-activating-factor 1 (Apaf-1), this complex will 
also require the binding of dATP as a cofactor to form the apoptosome complex which will be 
responsible for activation of caspase-9 (Purring-Koch and McLendon 2000). Active caspase-9 
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will lead to protease cascade which will eventually lead to cleavage of caspase-3 causing 
apoptosis (Li et al. 1997)   
(ii) Extrinsic pathway 
The extrinsic pathway involves cell members of the tumour necrosis factor-alpha (TNF-α) 
superfamily. These are receptors found on the cell surface, several members have been identified 
so far and they include TRAIL-1 and TRAIL-2, TNFR-1, CD-95, Fas, DR6 and NGFR (Chen 
and Wang 2002; Lavrik et al. 2005). An appropriate ligand has to bind to one of the receptors on 
the cell surface; this will lead to recruitment and activation of caspase-8 and -10 which are part 
of a proteinase family called caspases to form the death inducing signalling complex (Boatright 
and Salvesen 2003). This will then lead to activation of effector caspases or indirectly activate 
downstream caspases which will then lead to apoptosis (Schuler and Green 2001).    
There are a number of regulatory proteins that have been implicated in influencing cells to 
undergo apoptosis. However, there are two key regulatory proteins that have been largely 
conserved in species; they exist as multigene families with multiple homologues. They are 
known as Bcl-2 (family of inhibitors and promoters of apoptosis) and the p53 tumour suppressor 
gene and both have been extensively researched in breast cancer (Parton et al. 2009). DNA 
damage could activate p53 which may act as an inducer of apoptosis (Kopper and Petak  2008). 
1.6 Tumour suppressor genes 
The occurrence of cancer is usually owed to gain of function mutation of proto-oncogenes, 
converting them to oncogenes, or loss of function mutations which occur in tumour suppressor 
genes (Garg 2007). The first to be discovered was RB1, whose mutations were found to be the 
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main cause of retinoblastoma (Friend et al. 1986). Another one which has been highly studied is 
p53, both these will be discussed in the following sections. 
1.6.1 p53 
p53, one of the most highly studied tumour suppressor, is important for preventing proliferation 
of cancer cells thereby playing an important role in maintaining genomic integrity. It is due to 
this crucial role that it is also known as the guardian of the genome. This role is vital in 
preventing development of various cancers (Barnes and Camplejohn 1996; Potten and Wilson 
2004). The gene p53 encodes a protein p53; it is this protein that plays an important role in 
cellular processes involved in DNA damage recognition and repair, thereby preventing 
proliferation of abnormal cells. The p53 protein is normally present in low concentrations and in 
some cells; it may even be latent or inactive. This is mediated by Mdm2 which binds to p53 and 
decreases its stability and half-life through the ubiquitin-proteasome pathway, requiring some 
kind of signal for it to be active (Lee and Lozano 2006; Levine 1997).   
Following DNA damage, expression of activated oncogenes or other stressful events in normal 
cells, p53 is rapidly activated in high amounts which are proportional to the severity of the DNA 
damage and acts as a checkpoint factor, allowing cells to either undergo apoptosis or cell cycle 
arrest at the G1-phase (Gasco et al. 2002; Giono and Manfredi  2006). p53 may also act as an 
effector protein, allowing expression of genes involved in cell damage control and repair by 
interacting with proteins involved in DNA damage recognition and sending signals to those 
repair genes (Potten and Wilson 2004). The importance of having a functional p53 protein was 
further shown in mice with a null mutation that was introduced in the p53 gene and it was found 
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that mice with a homozygous null mutation in p53 had a high incidence of spontaneous tumours 
from a very early age (Donehower et al. 1992). 
Of over 2500 human cancer tumours that have been analyzed, p53 has been found to be mutated 
in over 50% of them (Potten and Wilson 2004). Humans with a mutant germ line p53 gene 
develop Li-Fraumeni syndrome and are more easily prone to developing cancer (Hainaut and 
Hollstein 2000).  
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(Constructed using protein lounge) 
Figure 1.2: A simplified diagrammatic representation of the p53 pathway.  
In normal cells, p53-mdm2 autoregulatory feedback loop regulates amounts of p53 and keeps 
them low. Upon exposure to DNA damage, mdm2 is inhibited. This triggers p53, leading to 
transcription of its downstream targets, e.g. Bax, Bcl2 and cytochrome c, eventually resulting in 
apoptosis.  
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1.6.2 Retinoblastoma tumour suppressor gene (RB) 
Retinoblastoma tumour suppressor gene (RB) encodes the retinoblastoma protein (pRb or Rb) 
which is dysfunctional in many types of cancer. It belongs to a ―protein pocket‖ family whose 
members possess a highly conserved sequence in that pocket domain; they interact with specific 
cellular proteins to mediate certain effects (Poznic 2009). The main function of the pRb is 
believed to be a signal transducer between the cell cycle and its transcriptional machinery (Zhu 
2005). This protein regulates the G1 to S transition by binding to E2F and inhibiting promoters 
of expression genes required for transition through this phase (Poznic 2009). It functions to 
inhibit cell proliferation and is important for regulation of transcriptional factors that play a role 
in cellular differentiation, and ensures permanent withdrawal from the cell cycle once cell is 
differentiated (Poznic 2009; Weinberg 1995).  
The protein Rb is thought to be a tumour suppressor; however, the mechanism of how it controls 
apoptosis is not yet clear. By genetically engineered mouse models, it has been speculated that it 
may trigger apoptosis by different pathways, the most studied being that as a regulator of E2F 
(Lee 2002; Zhu 2005). E2F transcriptional factors not only have a role in the cell cycle, but also 
regulate expression of pro-apoptotic proteins, then due to Rb’s ability to repress E2F, and then it 
can repress expression of these pro-apoptotic proteins such as cyclin E, CDC6 and CDK1 
(MacLeod 2010). 
Mutations in RB were first established to be the sole cause of retinoblastoma. Mutations in RB 
gene leads to production of a dysfunctional protein which may lead to increased uncontrolled 
proliferation and cancer. It has been further studied and has been found to be mutated in a third 
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of human cancers (Lee 2002).The Rb tumour suppressor pathway has been found to be one of 
the most common disrupted pathways in hepatocellular carcinoma (Mayhew et al. 2007). 
1.6.3 RBBP6 
Retinoblastoma binding protein (RBBP6), also known as potential related protein (P2P-R) or 
p53-associated cellular protein-testes derived (PACT) is a 250-kDa multidomain protein (Chibi 
et al. 2008; Li et al. 2007). The tumour suppressors p53 and Rb require specific protein to 
protein interactions to mediate their respective functions. RBBP 6 protein is one of very few 
proteins known to interact with both p53 and Rb tumour suppressors (Ntwasa 2008; Simons et 
al. 1997). RBBP6 consists of a conserved N-terminal domain known as the DWNN, a zinc finger 
and a conserved ring finger like motif (Pugh et al. 2006). It was identified by human genomic 
libraries for its binding properties to the tumour suppressor Rb. It binds to unphosphorylated Rb 
but not phosphorylated Rb on a region near the C-terminus (Sakai et al. 1995).  
Even though the physiological role of p53-RBBP6 interaction has not been clearly understood, 
recent studies have given better insight on this interaction. Li et al. (2007) looked at the p53-
RBBP6 interaction in mice. They found that RBBP6 is a negative regulator of p53, and it does 
this through physical interaction with mdm2, its primary regulator leading to p53 ubiquitination. 
Overall, they found that RBBP6 could inhibit p53 by promoting its degradation. 
1.7 Plant extracts as anti-cancer drugs 
Over the years, research on plants as anti-cancer agents has involved collection and 
identification of plants, which is done by a botanist, and then crude extracts are prepared from 
the plant material for biological screening done by phytochemists, followed by isolation of the 
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active compound or compounds (Balunas and Kinghorn 2005). Even though interest in 
medicinal plants may only have been for a couple of decades, a number of important drugs have 
stemmed from the different researchers and today a lot of these drugs made from natural 
products are widely used worldwide. Of over 50 FDA approved drugs that are used for 
chemotherapy, many are derived from natural sources e.g., Taxol, Camptothecin, Podofilox, 
Oncovin and Velban etc. which are derived from the plants Taxus brevifolia, Camptotheca 
acuminate,  Podophyllum peltatum and Catharanthus roseus, respectively (Itokawa et al. 2008; 
Pezzuto 1997). 
1.7.1 Taxol  
Taxol, a diterpene alkaloid was first discovered and isolated in the 1960s from the bark of a tree 
Taxus brevifolia (also known as Pacific yew or Western yew) (Guchelaar et al. 1994; Nicolaou et 
al. 1994). It became highly talked about in the 1980s and 1990s in America because it 
demonstrated efficacy as an anti-cancer agent. It has been approved for use in the treatment 
against metastatic breast and ovarian cancer in most countries around the world and is currently 
the best-selling anti-cancer drug. In America, it has also been approved for use in treating 
Kaposi’s sarcoma and non-small lung cancer, its potential to treat others cancers continues to 
grow (Goodman and Walsh 2001).  
Taxol’s antitumour mechanism derives from its activity on microtubules. Microtubules are 
crucial in the cell since they play an important role in the cell’s mitotic functions, cellular 
motility and cell shape. Taxol acts by binding to the microtubules promoting their assembly and 
stabilising them (Rowinsky et al. 1990). The stabilising of the microtubules prevents them from 
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depolymerising, and thus, this blocks the G1 or M stage of the cell cycle, preventing cells from 
undergoing cell division (Arnal and Wade 1995). 
1.7.2 Camptothecin 
Camptothecin is an alkaloid that can be isolated from the leaves, bark and fruit of Camptotheca 
acuminate tree (also known as Nyssaceae) (van Hengel et al. 1992). This plant is native to India 
but was introduced into the U.S.A. in the 1950s to test for potential anti-tumour, anti-viral and 
antibiotic properties, it was later found to have high anti-tumour properties (Potmesil 1994; Wall 
and Wani 1996). Camptothecin acts by binding to and strongly inhibiting DNA topoisomerase I, 
an enzyme important in DNA replication, thus, preventing DNA and RNA synthesis (Kessel et 
al. 1972; Kjeldsen 1992). The problem with this drug is that it is poorly soluble. It has shown 
anti-tumour activity on colon and gastric tumours, but it also showed hematological toxic effects. 
This lead to an interest in producing camptothecin analogues which are more soluble.  To date, 
two camptothecin analogues have been approved by the FDA. Topotecan is one such analogue, it 
is water soluble and has been found to be effective against many tumours including ovarian and 
colon tumours. The second is irinotecan, which is a more potent camptothecin analogue; it is 
primarily used in the treatment of colorectal cancers (Hind 2008; Pizzolato and Saltz 2003).  
1.7.3 Podofilox 
Podofilox (podophyllotoxin), and its derivatives etoposide and teniposide are extracted from 
rhizomes of Berberidaceae family Podophyllum peltatum, Podophyllum emodi or Podophyllum 
hexandrum (Giri and Narasu 2000). Podofilox has shown to be effective in the treatment of 
genital warts (Condyloma acuminatum). These warts are as a result of a sexually transmitted 
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disease caused by the human papillomavirus (HPV), which has strains that have the potential to 
cause cervical and genital cancer (Beutner et al. 1989; Bonnez 1994). Etoposide is used to treat 
leukemia, ovarian cancer and Hodgkin’s disease. Teniposide is used to treat leukemia, brain and 
bladder tumours (Giri and Narasu 2000). Podophyllotoxin acts by inhibiting microtubule 
assembly at the beginning of metaphase thereby preventing cell division. The derivatives act in a 
different manner, they prevent DNA replication at the S-phase and they also bind to and inhibit 
DNA topoisomerase II (Giri and Narasu 2000). 
1.7.4 Velban (vinblastine), vincristine, vinorelbine and vindesine 
Vincristine, and vinorelbine and their synthetic derivatives vindesine and vinblastine are vinca 
alkaloids isolated from the periwinkle plant Catharanthus roseus (Hait et al. 2007; Ngan et al. 
2000). These vinca alkaloids are potent inhibitors of cell proliferation and have been found to 
exhibit different cytotoxicities to different cancers. Vinblastine is used to treat non-Hodgkin’s 
lymphoma, testicular and breast cancer. Vincristine is effective against Hodgkin’s disease and 
paediatric cancers. Vinorelbine is effective against metastatic breast cancer and ovarian cancer 
and has been approved for use against non-small lung cancer. (Aniszewski 2007; Hait et al. 
2007).  Vindesine has been found to be effective against metastatic breast cancer (Hansen and 
Brickner, 1984). Vinca alkaloids act by binding to depolymerized mitotic spindle microtubules, 
preventing their assembly (Hait et al. 2007; Ngan et al. 2000). This then brings about mitotic 
arrest at early metaphase (Weaver and Cleveland 2005). 
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1.8 AIMS AND OBJECTIVES  
The aim of this study was to investigate the anti-tumour properties of 3 southern African plants 
on breast cancer cell lines. For those that exhibit a significant level of cytotoxicity, their 
mechanism of death induction to the cells was evaluated, to determine whether death was 
occurring via apoptosis or necrosis. Since apoptosis is the ideal method of death induction, we 
aimed to see if these plant extracts had an effect on some of the major genes involved in 
apoptosis being p53 and RBBP6. This was done with the aim of assisting in developing future 
targeted therapeutic strategies that prevent deregulation of these genes, thereby allowing their 
regulated expression to induce apoptosis in potential breast cancer cells. 
Objectives of the study 
 To evaluate the antiproliferative activity of three crude plant extracts: Kedrostis 
foetidissima, Euphorbia mauritanica and Elytropappus rhinocerotis against two 
human breast cancer cell lines namely: MCF-7 and YMB-1. 
 To determine whether apoptosis is the induced mode of cell death by the extracts on 
the breast cancer cell lines. 
 To determine if the herbal extracts that exhibit cytotoxicity on the breast cancer cell 
lines affect the apoptotic genes p53 and RBBP6. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Breast cancer cell lines 
The following breast cancer cell lines were used in this study: YMB-1 (human breast carcinoma, 
polygonal epithelial cell line) and MCF-7 (human breast adenocarcinoma, mammary epithelial 
cell line). YMB-1 cells are aggressive squamous cells whilst MCF-7 cells are less aggressive 
adenocarcinoma, both cell lines were obtained from Japan Health Resource Centre. The two cell 
lines were included to test if the herbal extracts would induce the same effect on different cell 
lines. 
In a study of this nature, it would have been ideal to include a normal breast cell line. However, 
this was not possible for the following reasons. Normal breast cells undergo a limited number of 
cell divisions and readily enter senescence under in vitro conditions. This clearly poses a 
problem for i) the maintenance of large quantities of uniform cell populations and ii) when the 
primary goal of the analyses is to assess programmed cell death. In attempting to address this 
issue, some researchers have made use of oncogenic (viral/cellular) or carcinogenic e.g., 
benzo[a]pyrene (B[a]P) transformation to give the cells ―extended life‖.  It can then be argued, 
however, that this defeats the whole purpose of keeping the cells ―normal‖ (Wazer et al. 1995).  
Nevertheless, the herbal extracts were screened for cytotoxicity on MRC5 fibroblast cells in the 
lab by Thafeni (unpublished) and results are shown in appendix D. 
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2.1.2 Plant collection  
The three herbal extracts used in this study: Kedrostis foetidissima, Euphorbia mauritanica and 
Elytropappus rhinocerotis were collected from various locations around South Africa. The 
specimens were obtained from the School of Molecular and Life Sciences, University of 
Limpopo.  
2.1.3 Plant extraction 
The stems and leaves were collected, washed and frozen. The frozen plant material was ground 
to a fine powder in liquid nitrogen using a warring blender. Once ground, the plant material was 
weighed and extracted using absolute methanol (1 g/10 ml, w/v) at room temperature for 24 
hours. The resulting extract was filtered through a Whatman filter paper, and then the filtrate was 
dried at 40°C under low pressure using a Büchi rotavapor R-205 (Büchi Labortechnik AG, 
Switzerland). Once dried, the extract was weighed and dissolved in 100% dimethyl sulfoxide 
(DMSO, Sigma) to the desired concentration and stored as a stock solution in an airtight 
container at -20°C until use. 
2.1.4 Cell culture expansion  
MCF-7 breast cancer cells were routinely cultured in 25 cm
2 
tissue culture flasks with minimum 
essential media (MEM with L-glutamine, Sigma) supplemented with 10% fetal bovine serum 
(FBS, Sigma) and 1% penicillin/streptomycin (Sigma). YMB-1 cells were cultured in 25 cm
2
 
tissue culture flasks with RPMI-1640 (Sigma) media supplemented with 10% FBS and 1% 
penicillin/streptomycin. The cells were incubated at 37ºC, 95% humidity and 5% CO2.  
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2.2 Experimental assays 
2.2.1 MTT assay 
The MTT {3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide} assay is a simple 
colorimetric assay used to measure cell cytotoxicity, proliferation or viability. MTT is a pale 
yellow substrate which enters live cells and passes into the mitochondria to produce a dark blue 
insoluble formazan. It is converted to formazan by cleavage of the tetrazolium ring by  
dehydrogenase enzymes of viable cells. The formazan requires an organic solvent to be 
solubilised; the solubilised formazan can then be measured on a spectrophotometer (Mosmann, 
1983). Since MTT can only be reduced in metabolically active cells, it can thus be used to 
determine the amount of viable cells versus the dead ones. For this study, this assay was used to 
measure the effect of liquid plant extract on breast cancer cell viability.  
Ninety six well tissue culture plates were used to culture cells for the MTT assay. Into each well, 
5 x 10
3
 cells in 90 µl of media were seeded. These were then incubated overnight. Cells were 
treated with varying concentrations of the herbal extracts (10, 30, 50 and 100 µg/ ml, w/v); these 
were prepared from 40 ng/ml stock solution by diluting with either supplemented MEM or 
RPMI-1640 media. A non-treatment control (cells, media and later MTT) and a blank (only cells 
and media) were included. Cells were treated over a period of 24 hours. This was followed by 
addition of 10 µl of MTT (Sigma) (prepared to 5 mg/ml 1x PBS at 37°C) into each well except 
for the blank, these were further incubated for 4 hours. To dissolve the formazan crystals formed, 
90 µl of DMSO was added into each well and the plate was read using Bio-Rad Microplate 
reader at an absorbance of 570 nm. 
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Percentage Cell Viability was calculated as follows: 
% Cell viability = Absorbance of treated cells – Absorbance of blank     X 100 
                            Absorbance of untreated cells – Absorbance of blank 
2.2.2 Flow cytometry 
The flow cytometer is highly sophisticated equipment used to analyse individual cells in 
heterogeneous populations. It allows thousands of cells to pass through a light beam every 
second (Potten and Wilson 2004), and then it can distinguish these cells based on size and health 
amongst other parameters. This technique was employed following the MTT assay to investigate 
whether the herbal extracts were inducing cytotoxity to the cells by either necrosis or apoptosis. 
Annexin V (Ambion Annexin V-FITC Apoptosis Detection Kit) was used to quantitate the 
percentage of cells undergoing apoptosis, necrosis and viable cells. Annexin V has high calcium 
dependent affinity to phosphatidylserine residues; these residues are normally embedded in the 
cytoplasmic plasma membrane in healthy cells but are translocated to the surface of the cells 
during apoptosis. Therefore, Annexin V can bind to these residues acting as a probe to detect and 
measure apoptosis.      
MCF-7 and YMB-1 cells (1x10
5
) were incubated overnight. They were then treated with plant 
extract at a concentration that induced ~50% cell death and incubated for 24 hours.  Suspended 
YMB-1 cells were collected by centrifugation whilst attached MCF-7 cells were detached by 
trypsinization (Trypsin-EDTA, Sigma). MCF-7 cells were rinsed twice with 2 ml MEM and 
YMB-1 with RPMI-1640 at 37°C. The cells were resuspended in 500 µl of 1x Annexin V 
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Binding Buffer. This was followed by addition of 5 µl of Annexin V-FITC and 5 µl propidium 
iodide and 5 minutes incubation. The cells we then analysed by flow cytometry.  
2.2.3 RNA extraction 
Since RNA is highly susceptible to degradation, safety measures were taken throughout the 
processing steps to minimize its degradation. Working surfaces, glassware, pipettors and gloves 
were sprayed with RNaseZAP (Sigma) to eliminate RNase.  RNA was isolated from treated and 
untreated cells using the High Pure RNA Isolation Kit (Roche). This kit is designed to extract 
total RNA from cultured cells; it includes a DNAse digestion step which aims to remove all 
contaminating DNA from the RNA. Before RNA extraction, cultured cells were rinsed twice 
with 2 ml 1x PBS (Sigma) at 37ºC then RNA was extracted using RNA Isolation Kit according 
to manufacturer’s specifications, (see Appendix A1). Resulting RNA was quantified using a 
nanodrop (NanoDrop technologies, USA), reading was taken at 260A, A260/A280 ratio of ~2.0 
was regarded as pure. 
2.2.4 Reverse transcription 
For one step Real time PCR (RT-PCR), mRNA had to first be reverse transcribed to cDNA. This 
process was conducted following RNA extraction and it employs the use of specific primers with 
sequence complementary to the mRNA site where reverse transcription is meant to initiate. 
Extracted RNA was reverse transcribed using the ImProm-II Reverse Transcription System 
(Promega). Sequence specific primers were selected for use to generate specific cDNAs from the 
RNA target. The reverse transcription cocktail (see Appendix A2) was prepared in PCR tubes to 
a final volume of 20 µl. The tubes with the reverse transcription cocktail were briefly vortexed 
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then placed into the Multigene Gradient Thermal cycler system (Labnet International, Inc). The 
RNA was reverse transcribed under the conditions explained in Appendix A3. The resulting 
cDNA was used for one-step Real Time (RT)-PCR. 
2.2.5 Real Time PCR (RT-PCR) 
Real time polymerase chain reaction is the most sensitive technique for simultaneous mRNA 
detection and quantification. It has been the preferred method of choice for quantitating changes 
in gene expression patterns. It can be used to quantify mRNA levels from much smaller samples, 
such as mRNA from a single cell.  
To monitor cDNA amplification in RT-PCR, SYBR Green JumpStart Taq Ready Mix (Sigma) 
was used in our study. It contains JumpStart Taq DNA polymerase and only requires addition of 
template, primers and water. It is a fluorescent intercalating dye which presents the simplest and 
cheapest way of detecting PCR product in real time. The dye will only fluoresce when bound to 
double stranded DNA, thus allowing for fluorescence to increase as the number of double 
stranded DNA increases, this allows for DNA concentration to be quantified at each cycle. The 
real-time PCR cocktail is explained in Appendix A4. 
Quantitative analysis of the mRNA transcripts was carried out using the Roche lightcycler. The 
parameters on the machine were set as follows: 
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Table 2.1: Real Time PCR parameters. 
Analysis Cycle Segment Temperature in °C Hold time 
Enzyme 
activation 
1 1 95 2 minutes 
Quantification 35- 45 Amplification 
Denaturation 
Annealing 
Extension 
 
95 
55 
72 
 
45 seconds 
45 seconds 
45 seconds 
None 1 Final extension 72 10 minutes 
Melting  1 Melting curve 
Denaturation 
Annealing 
Extension 
 
95 
65 
95 
 
10 seconds 
15 seconds 
0.1°C/Sec 
None 1 Cooling 40 30 seconds 
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CHAPTER 3 SCREENING INDIGENOUS SOUTH AFRICAN PLANTS 
FOR CYTOTOXICITY ON BREAST CANCER 
3.1 Introduction 
South Africa has a remarkably rich flora biodiversity, comprising of about 8% (20 000) of the 
world’s plant species. Of these, about 20% (3689) are used as medicine, and from these, about 
350 are commonly used and traded medicinal plants (Cherry 2005; Van Wyk et al. 2008). A 
great proportion of black South Africans rely on traditional medicine, with about 70-80% 
consulting with traditional healers as a source of primary healthcare. Traditional healers use 
various traditional indigenous plants to heal different ailments. They either use the roots, stems 
or leaves of individual plants or combinations of a number of these plants. 
 However, a great number of people harvest their own plants or obtain them from local muthi 
vendors. This vast usage of medicinal plants stems from the fact that these plants are easily 
accessible or can be obtained at a very affordable price. Indigenous knowledge on the use of 
these medicinal plants has been passed down from generation to generation, providing great 
expertise on their ethnobotanical use. This has allowed for these natural plant medicines to have 
been tested for efficacy and side effects throughout human history. The obstacle faced however, 
is little or no knowledge on the molecular mechanisms of active compounds and the chemical 
profiles of these plants (Lee et al. 2010). Hence, it is imperative for those plants which have been 
used traditionally as medicine for treatment of various diseases, that they undergo 
pharmacological and biological studies to test for their activities and efficacy. 
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3.2 Kedrostis foetidissima 
3.2.1 Classification 
Kedrostis foetidissima, also called Utuvishe in Xhosa belongs to a group of plants known as 
cucurbitacins. Cucurbitacins are a group of bitter tasting plants mostly found in the plant family 
Curcubitaceae. There are however, a few other cucurbitacins that may be found in other plant 
kingdoms (Miro 1995). Cucurbitacins are a fairly large family comprising about 130 genera and 
900 species (Jeffrey 1980). The characteristic constituent of this family of plants are 
cucurbitacins, these are tetracyclic triterpenoids derived from the skeleton of these plants. 
Cucurbitacins are all named after successive letters of the alphabet from A to R. Cucurbitacins B 
and D are the most common in the plant kingdom.  A previous study identified cucurbitacins B, 
D, E and I as present in K. foetidissima (Miro 1995).  
3.2.2 Botanical description 
Kedrostis foetidissima is a leguminous herb. It is a succulent perennial climber with a very 
unpleasant smell. It grows to a height of between 0, 3-3 metres (Figure3.1). 
3.2.3 Geographical distribution 
The distribution of K. foetidissima stems in the southern African region including Namibia, 
Botswana through to Gauteng, KwaZulu-Natal, Limpopo, Mpumalanga, Northwest and Northern 
Cape [South African National Biodiversity Institute (SANBI)]. 
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3.2.4 Traditional medicinal use 
Fruits belonging to the cucurbitacins family have been used for centuries due to the wide range 
of biological activities they exhibit. They are useful for human health due to their ability to act as 
natural laxatives, to treat liver diseases and inflammatory response such as rheumatism amongst 
others. Other species have been found to exhibit insecticidal, antifungal and antibacterial 
properties. These plants have been of great interest in scientific research and a number of 
compounds from this group have been investigated for antitumour activities and positive effects 
on cardiovascular health (Miro 1995; Rahman 2008). 
Kedrostis foetidissima has been used by tribes throughout Africa to treat various human and 
livestock ailments. It is used by the Masai people in Kenya to treat cattle suffering from bloat; 
crushed plant is feed to the ailing cattle; they also use it to treat children suffering from measles, 
the crushed plant is added to bath water of the sick children (Ole-Miaron 2003). The Zay people 
in Ethiopia use it to treat chest pains (Giday et al. 2003). Tanzanians use it to treat measles 
(Otieno et al. 2007). In South Africa, especially in the Xhosa culture, an infusion of the tuber is 
used as a ritual wash to bring luck, a piece can also be put under the tongue during times of 
trouble e.g., in court cases (Cocks and Dold  2006)   
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Figure 3.1: Kedrostis foetidissima (Curcubitaceae).  
A perennial climber with a simple tendril (left). Geographical distribution of K. foetidissima in 
Southern Africa (right). (http://www.bihrmann.com/audiciforms/SUBS/ked-foe-sub.asp and 
SANBI) 
3.3 Euphorbia mauritanica 
3.3.1 Classification 
Euphorbia mauritanica belongs to a genus called Euphorbia. This genus belongs to a family of 
plants known Euphorbiaceae. Euphorbiaceae is the most diverse genera with over 2000 species. 
Of these 2000 species over 200 can be found in South Africa alone (Pienaar 1984; Webster 1994; 
Zimmermann 2010).  
3.3.2 Geographical distribution 
The Euphorbia genus can be found all over the world, e.g., Arabia, Morocco, Canary Islands and 
South Africa amongst others (Jacobsen 1946). They occur mostly in temperate regions, with 
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most of the succulent species being indigenous to South Africa. Euphorbia mauritanica is mostly 
dominant in KwaZulu-Natal, Northern Cape, Western Cape, Eastern Cape, Free State as well as 
Namibia and Lesotho (Pienaar 1984).  
3.3.3 Botanical description 
Euphorbiaceae display a wide range of growth morphologies ranging from annual and perennial 
herbs, succulents to trees and shrubs. Euphorbia mauritanica, also known as Yellow milk bush, 
Gifmelkbos and Jakkalskos is a freely branched succulent shrub that produces yellow flowers in 
spring. It can grow to a height of between 0,07 -2,74 metres (Figure 3.2). The leaves are up to 1, 
3 cm long, which are only on young growing stems. It has smooth green branches which produce 
white milky latex. It produces fruit with a three chambered capsule, with each capsule containing 
a seed (Pienaar 1984; Webster 1994; Botha and Venter 2002; Zimmermann, 2010). 
3.3.4 Traditional medicinal use 
Plants of the Euphorbiaceae family have a long history of use as traditional medicine. In Africa 
and Fiji, a decoction or maceration of some Euphorbiaceae plants are used to treat asthma, 
cough, diabetes, cure ear-ache, bowel complaints and infertility (Singh 1986; Igoli et al. 2005). 
Some have been used for centuries as traditional medicine against cancers and tumours (Rizk 
1987). In countries like Egypt, Euphorbia species are widely used in the treatment of stomach, 
uterus, liver and kidney cancer (Sayed 1980). The root of E. mauritanica is infused in boiling 
water and used to treat toothache. Euphorbia mauritanica’s latex is used as treatment for warts 
(van Wyk et al. 2008). 
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Figure 3.2: Euphorbia mauritanica (Euphorbiaceae).  
A shrub producing yellow flowers in spring (left). Geographical distribution of E. mauritanica in 
southern Africa (right) (http://sophy.u-3mrs.fr/Afriqsud/Photo-cpAFS /E/ 
Euphorbia_mauritanica and SANBI) 
From section 1.5, it is evident that plants have shown great potential in anti-cancer therapeutics. 
South Africa with its huge biodiversity is also playing a role in production of medicine used 
around the world. Some of the most popular medicine such as Cape aloe (Aloe ferox) and devil’s 
claw (Harpagophytum procumbens) are indigenous to South Africa (van Wyk 2008). It is now 
up to scientists to explore other indigenous plants, especially those that have been used for 
centuries by South African people to treat different ailments for potential anti-cancer activities. 
For this study, we aimed to investigate the possible antiproliferative properties of the 3 southern 
African herbal extracts, namely: Kedrostis foetidissima, Euphorbia mauritanica and 
Elytropappus rhinocerotis against breast cancer cells. This was done by conducting an MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, and the IC50 was 
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determined. All experiments were repeated at least five times (five assays with eight replicates) 
to ensure accuracy of the results. 
3.4 Results and discussion 
MTT assay is a cell cytotoxicity or viability assay. The three herbal extracts were screened for 
their possible antiproliferative effect against YMB-1 and MCF-7 breast cancer cell lines. The 
MTT assay method used is described in Chapter 2, Section 2.2.1. Results obtained suggest the 
crude extracts of the plant Elytropappus rhinocerotis did not exhibit any antiproliferative activity 
against either MCF-7 or YMB-1 breast cancer cell lines, showing very minimal activity at the 
highest concentration tested of 100 µg/ml, following 24 hour treatment (see Appendix A).  
Results observed for E. rhinocerotis in this study correlate with those obtained in a study by 
Essack (2006) whereby the cytotoxicity of E. rhinocerotis on MCF-7 cells was tested; the results 
obtained in that study suggested that the herbal extract exhibited insignificant antiproliferative 
activity. At a concentration of 5 mg/ml, cell death of less than 20% would be considered 
negligible (Essack 2006). It is interesting to note that they studied the herbal extract at high 
concentrations of between 0,625-5 mg/ml whilst in our study the concentrations ranged between 
10-100 µg/ml. This may suggest that E. rhinocerotis generally does not have any 
antiproliferative properties on MCF-7 and YMB-1 cell lines; however, further studies testing 
much higher concentrations of this plant extract may be required to completely rule out its 
cytotoxicity against MCF-7 and YMB-1 breast cancer cells. 
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Figure 3.3: Cytotoxicity effects of the herbal extracts Kedrostis foetidisima A) and 
Euphorbia mauritanica B) on MCF-7 breast cancer cells.  
Cells were treated for 24 hours at increasing concentrations of 10, 30, 50 and 100 µg/ml using 
the plant aqueous extracts. 25 nM-S represents the positive control, staurospaurine, at a 
concentration of 25 nM. n = 5, p < 0.05. 
B 
A 
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Figure 3.4: Cytotoxicity effects of the herbal extracts Kedrostis foetidisima A) and 
Euphorbia mauritanica B) on YMB-1 breast cancer cells.  
Cells were treated for 24 hours at increasing concentrations of 10, 30, 50 and 100 µg/ml using 
the plant aqueous extracts. A staurospaurine control was included. 25 nM-S represents the 
positive control, staurospaurine, at a concentration of 25 nM. n = 5, p < 0.05 
A 
B 
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The antiproliferative activity of the herbal plant extracts on the breast cancer cell lines was 
measured using the IC50 value principle, which is a principle based on the concentration of the 
plant extract that causes 50% cell death. The lower the IC50 value of an extract on a cell line, the 
more potent it is considered to be. The aqueous extracts of both the herbal plants Kedrostis 
foetidissima and Euphorbia mauritanica exhibited considerable levels of antiproliferative 
activity against MCF-7 breast cancer cells presented in Figure 3.3.  
Treatment with K. foetidissima at a concentration of 100 µg/ml induced 48% cell death (IC50 
>100 µg/ml) (Figure 3.3 A). Euphorbia mauritanica induced 40% cell death at a concentration 
of 100 µg/ml (IC50 >100 µg/ml) (Figure 3.3. B). The positive control, staurospaurine induced 
43% cell death at a concentration of 25 nM. In a previous study aimed at investigating the 
possible antiproliferative properties of E. mauritanica on MCF-7 cells (Essack 2006), no 
significant cytotoxicity could be observed, with less than 10% cell death being observed even at 
a high concentration of 5 mg/ml. Results were contrary to what was observed in this study with 
40% cell death resulting from a much lower concentration of 100 µg/ml. 
In addition to the cell cytotoxicity assay for K. foetidissima and E. mauritanica on MCF-7 breast 
cancer cells, we aimed to investigate the possible antiproliferative effects of these herbal extracts 
on a different breast cancer cell line. Hence their cytotoxicity was tested on YMB-1 cell lines. 
The positive control, staurospaurine, induced 42% cell death at a concentration of 25nM on the 
YMB-1 cells.  On comparing to the cytotoxicity of K. foetidissima on YMB-1 to MCF-7, it was  
observed that K. foetidissima  extract exhibited a slightly higher cytotoxicity on YMB-1 cells, 
with 53% cell cytotoxicity being observed at a concentration of 100 µg/ml and 37% cytotoxicity 
at a concentration of 50 µg/ml, meaning 50 µg/ml<IC50>100 µg/ml (Figure 4.2. A). For MCF-7 
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cells, an IC50>100 µg/ml was observed. The second herbal extract E. mauritanica however, 
exhibited an insignificant amount of cytotoxicity on YMB-1 cells, with less than 20% cell death 
occurring at a concentration of 100 µg/ml whilst 40% cell death was observed for MCF-7 at the 
same concentration. These results indicate that the induced cytotoxicity is cell line specific; 
hence the two cell lines exhibited different levels of sensitivity to E. mauritanica extract.  
Most plants which have been used as traditional medicine for the treatment of cancer and 
inflammation are high in cucurbitacins (Rios et al. 2005). Research into antiproliferative 
properties of various cucurbitacins has led to interesting discoveries, where cucurbitacins B, D 
and R, isolated from Begonia heracleifolia were found to exhibit cytotoxicity to prostate and 
nasopharyngeal cancer at IC50 ranging between 0,003 and 3, 81 µg/ml (Rios et al. 2005). These 
exhibited a high level of cytotoxicity. For our study, a significant level of cytotoxicity was still 
induced by K. foetidissima on both MCF-7 and YMB-1 cell lines, whose IC50 was at 
concentrations of between 50 and 100 µg/ml. Another study observed that cucurbitacins B, D, E, 
I, J, K and L exhibited high cytotoxicity to Hela and KB human cell cultures with IC50 of 0.005-1 
µg/ml (Konopa et al. 1974). This research and other previous studies are all indicating promising 
results in the use of cucurbitacins as potential future therapeutics not only of breast cancer but 
other cancers as well. 
Plants of the Euphorbiaceae family have been used for centuries as traditional medicine against 
cancers and tumours (Rizk 1987). However, a large number of Euphorbia have not been 
scientifically screened for anti-cancer activity. Hence, we thus tested the cytotoxicity of the 
crude extracts of Euphorbia mauritanica on two breast cancer cell lines: MCF-7 and YMB-1. A 
survey on the chemical data isolated from over 120 Euphorbiaceae identified a large diversity of 
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structurally unique chemical compounds. These include methyl esters, their derivatives and 
diterpene polyesters. Other compounds identified include alkaloids, phenolic compounds, 
cyanogenic glucosides and glucosinolates (Rizk 1987).  Some of these chemical compounds 
have been shown to exhibit antiproliferative activity against various cancer cells. A study by 
Engi et al. (2007) looked at the effect of diterpenes isolated from methanol extracts of nine 
Euphorbia species on human colon cancer cells and observed a moderate antiproliferative effect 
of IC50< 3.5 μg/ml- 17.46 μg/ml.  
Studies by Whelan and Ryan (2003), investigated the effect of ethanolic extracts of Euphorbia 
species: E. grandidens, E. grandicorni, E. latea, E. coerulescens, E. trigona1, E. istigy, E. 
candelabrum, E. pentagona, E. triangularis against HEp-2 (Human epidermoid cancer) cells at 
concentrations of 8.53 μg/ml, 85.3 μg/ml and 853.9 μg/ml. They found that of the nine plant 
extracts tested, four extracts resulted in reduced cell viability at concentrations of 85.3 μg/ml and 
853.9 μg/ml, with the most potent extract causing IC50 at 57 μg/ml. Interestingly, for our study, 
we observed increase in proliferation for YMB-1 cells that were treated with E. mauritanica at a 
concentration of 10 µg/ml (Figure 3.4. B), in their study, they observed a similar trend with 
seven of their extracts also promoting cellular proliferation at a concentration of 8.53 μg/ml. This 
may indicate that some Euphorbia species, including E. mauritanica, may actually induce cell 
proliferation to some cancers at low doses.  
It was evident from our study that the crude extracts of the two plants E. mauritanica and K. 
foetidissima were exhibiting antiproliferative properties on the breast cancer cells, but the next 
important issue was to determine if the observed cytotoxicity was as a result of apoptosis or 
necrosis. 
39 
 
 
CHAPTER 4 SCREENING OF HERBAL EXTRACTS FOR MODE OF 
DEATH INDUCTION (APOPTOSIS OR NECROSIS) 
4.1 Introduction 
Apoptosis and necrosis are two different types of cell death characterised by different modes or 
morphologies of death (Figure 4.1). Apoptosis is a form of programmed cell death, whereby 
cells undergo orderly typical morphological changes whereas necrosis involves rapid lysis of a 
cell (Kumar 1998; Raffray and Cohen 1997). Necrosis is generally not the ideal death pathway 
since it leads to leakage of damaged internal components of the dying cell into surrounding 
tissue, which may be harmful to the surrounding cells, and leads to induction of an inflammatory 
response (Potten and Wilson 2004). 
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Table 4.1: Differences between apoptotic and necrotic cellular death pathways 
Apoptosis Necrosis 
Morphological features 
Early loss of cell to cell contact and involves single cells (d) Late loss of cell to cell contact and involves clusters (d) 
Anoikis- detachment from the surface  No anoikis  
Cell shrinkage (e) Cell swelling (e) 
Mitochondrial condensation, no swelling (a) Mitochondria swelling (a) 
DNA fragmentation- nuclear DNA breaks down in large, then 
small nucleosomal fragments (b) 
Nuclear swelling (e) 
Formation of apoptotic bodies No apoptotic bodies 
Rapid recognition, uptake and degradation of apoptotic bodies by 
phagocytes (c) 
No cellular uptake by phagocytes, attraction of inflammatory 
cells (c,e) 
No leakage of cell contents (a) Cells swell up and suddenly collapse, leading to spilling of cell 
contents (b) 
Apoptosis Necrosis 
Biochemical and molecular features 
ATP levels are preserved (e) Rapid intracellular ATP depletion (e) 
Oxidative stress (e) ___ 
Cytochrome C released from mitochondria (e) ___ 
Protein degradation mediated by specific proteolytic enzymes 
known as caspases (a) 
No regulated protein degradation (a) 
Plasma membrane remains intact almost until the end, then losses 
asymmetry and integrity. Phosphatidyl serine residues located in 
the inner plasma membrane translocate to the cell surface. (a,b) 
Plasma membrane losses integrity rapidly (b) 
Key: a) Kroemer et al. 1998; b) Fiers et al. 1999; c) Savill et al. 1993; d) Potten and Wilson 2004; e) Wlodkowic et al. 2009
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Figure 4.1: Characteristic features that distinguish between apoptotic and necrotic cell 
death (van der Meer et al. 2010).  
Necrotic cells are characterised by swelling up of the cell, loss of membrane integrity and 
eventually the cells lyse releasing their internal components into the surrounding tissue. 
Apoptotic cells shrink, chromatin condenses, nuclear DNA breaks down and apoptotic bodies 
form which are then phagocytosized by either macrophages or surrounding cells (van der Meer et 
al. 2010).  
Normal Cell 
Necrosis 
Formation of apoptotic 
bodies 
Cellular shrinkage, 
chromatin condensation 
Phagocytosis 
Cell swells up Cell disintegration 
Cell membrane becomes 
leaky 
Apoptosis 
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When working with potential therapeutic agents, it is important that they induce high 
cytotoxicity to their target cells whilst showing none or very minimal toxicity to the surrounding 
unaffected healthy tissue. From Table 4.1, it is clear that apoptosis would be the desired method 
of death since it is more regulated, considering the fact that dying cells are taken up by 
phagocytes and do not lyse to release their internal components to neighbouring cells, which 
would otherwise prove to be catastrophic.  
The purpose of this section was to screen the mode of death induction of the crude extracts of K. 
foetidissima on MCF-7 and YMB-1 cells and E. mauritanica on MCF-7 cells since they showed 
significant cytotoxicity on the cells. MCF-7 and YMB-1 breast cancer cells, treated with the 
herbal extract concentrations that induced about 50% cell death were incubated with Annexin V 
according to manufacturer’s specifications (see section 2.2.2). A negative control of untreated 
cells and positive control of cells treated with 25 nM of staurospaurine were included. 
Staurospaurine is a known inducer of apoptosis in many different cancer cell types (Motadi 
2009). Flow cytometry was employed to analyse the percentage of cells that underwent 
apoptosis compared to the percentage of necrotic and live cells following treatment with the 
herbal extracts. 
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4.2 Results and discussion 
The graphs below are representative of the flow cytometry apoptosis analysis    
  
 
   
Figure 4.2: Scatter analysis diagrams for YMB-1 cells.  
A) Untreated cells, B) Staurospaurine (25 nM) treated cells and C) Kedrostis foetidissima (100 
µg/ml) treated cells.  
 A  B 
 C 
2.29% 0.26% 
95.03
% 
2.42
% 
0.59% 2.77% 
57% 39.63% 
1.98% 1.58% 
60.26% 36.17% 
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Figure 4.3: Scatter analysis diagrams for MCF-7 cells.  
Cells were treated with A) Kedrostis foetidissima (100 µg/ml), B) Euphorbia mauritanica (100 
µg/ml), C) Staurospaurine (25 nM) and D) Untreated.  
A B 
C
 B  
D
 B  
0.90% 5.21% 
68.40% 25.49% 
0.60% 6.27% 
59.10% 34.10% 
1.04% 7.54% 
57.68% 33.75% 
0.59% 1.21% 
90.70% 7.50% 
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The cells were scattered into one of four quadrants: Quadrant B1 contains cells undergoing 
necrosis, quadrant B2 contains cells undergoing late apoptosis, quadrant B4 contains cells 
undergoing early apoptosis and quadrant B3 contains live cells (Figures 4.2 & 4.3). 
Since K. foetidissima seemed to be the only extract that exhibited cytotoxicity on YMB-1 cells, 
it was then further assessed for possible pro-apoptotic activity on this cell line. The YMB-1 cells 
were treated with K. foetidissima at a concentration of 100 µg/ml for 24 hours and tested for 
markers of apoptosis. On observing results for the positive control, staurospaurine (Figure 4.2 B) 
40% of the cells stained positive for externalised phosphatidylserine residues, indicating that 
40% of the cells underwent apoptosis whilst 57% remained alive. The cells treated with K. 
foetidissima extract demonstrated a similar percentage of phosphatidylserine externalisation to 
that of staurospaurine, with about 40% of cells undergoing apoptosis and about 60% remaining 
alive (Figure 4.2 C). A negative control of untreated cells was included which from flow 
cytometer analysis indicated that 95% of the cells were alive and less than 5% were dying 
naturally either via necrosis or apoptosis (Figure 4.2 A). The flow cytometer results suggested 
that the herbal extract K. foetidissima mainly induced cell death to YMB-1 cells via an apoptotic 
pathway.  
MCF-7 cells exhibited significant sensitivity to both herbal extracts E. mauritanica and K. 
foetidissima hence we then aimed to investigate if these herbal extracts were inducing death to 
the cells via necrosis or apoptosis. Similarly to the previous experiments, staurospaurine (25 nM) 
was used as a positive control, and the flow cytometry results suggested that over 40% of cells 
stained positive for externalised phosphatidylserine. MCF-7 cells were treated with both K. 
foetidissima and E. mauritanica at concentrations of 100 µg/ml. Flow cytometry analysis 
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indicated that treatment with K. foetidissima resulted in about 30% cells staining positive for 
externalised phosphatidylserine residues i.e. undergoing apoptosis and with almost 70% 
remaining alive. Euphorbia mauritanica treatment resulted in about 40% cells undergoing 
apoptosis whilst about 60% remained viable (Figure 4.6). A no treatment control was included 
which showed that over 90% of the cells were still alive after 24 hours and the rest of the cells 
had died mainly due to apoptosis (Figure 4.3). 
Extracts of K. foetidissima were assayed for markers of pro-apoptotic activity on MCF-7 and 
YMB-1 cell lines whilst E. mauritanica was assayed for markers of pro-apoptotic activity on 
MCF-7 cell lines only. On assessing cells in the second and fourth quadrant representing cells 
undergoing late and early apoptosis respectively, it was observed that K. foetidissima induced the 
highest apoptotic activity in YMB-1 than in MCF-7 cells (Figures 4.3C & 4.4A). This difference 
was also observed in the cytotoxicity assay. It is promising however, that the majority of cells 
were undergoing apoptosis in both cell lines. In a study by Essack (2006), contradictory results 
were obtained, with no phosphatidylserine residues externalisation being observed for MCF-7 
cells treated with E. mauritanica.  
In summary, the Annexin V apoptotic assay has demonstrated that the aqueous extracts of two 
South African herbal plants K. foetidissima and E. mauritanica induce their cytotoxic effects by 
an apoptotic mechanism. This indicates that these plants possess compound/s which can trigger 
an apoptotic pathway, which is promising in that induction of apoptosis correlates with anti-
proliferation of cancer cells. Even though regulation of apoptosis is controlled by a huge network 
comprising a number of genes, the two most important genes which have been found to be 
highly deregulated in cancer are p53 and RBBP6. Following the flow cytometry apoptotic assay, 
47 
 
we then aimed to investigate if these herbal extracts have any effect on these two tumour 
suppressor genes, using real-time PCR. 
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CHAPTER 5 TUMOUR SUPPRESSOR GENES 
5.1 Introduction 
The majority of breast cancers arise from deregulation of genes involved in the cell cycle or 
apoptosis. As with all drugs that are manufactured to treat different diseases, it is important for 
potential natural anti-cancer agents to exhibit a certain level of specificity on their target. The 
FDA approved chemotherapeutic drugs as mentioned in section 1.5 all exhibit specific activity 
on their target at various steps of the cell cycle. Their activity ranges from inhibiting microtubule 
assembly, to preventing DNA and RNA synthesis whilst some work by preventing DNA 
replication (Giri and Narasu 2000; Kessel et al. 1972; Kjeldsen 1992).    
Tumour suppressor genes have now become of great interest in understanding molecular 
pathogenesis of cancer. The tumours suppressors which have been highly found to be 
deregulated in breast cancer include p53 and RB genes. p53, a tumour suppressor is very crucial 
in the control of cell proliferation. Deregulation of p53 has been implicated in over 50% of 
cancers (Potten and Wilson 2004). This may stem from its role as a sequence specific DNA 
binding transcription factor, whose downstream targets are mostly gene products which control 
cell cycle arrest, DNA repair and apoptosis (Picksley and Lane 1994). Retinoblastoma (Rb), the 
first tumour suppressor to be discovered, acts as a crucial component of the cell cycle 
checkpoint. It functions to prevent excessive cell growth, by inhibiting progression of aberrant 
DNA along the cell cycle through G1 into the S-phase (Garg 2007; Mayhew et al. 2007). Rb has 
been found to be mutated in a third of human cancers (Lee 2002). From the extensive amount of 
research done on p53 and Rb deregulation, it can be said that they are arguably the most 
deregulated pathways in human cancer. The tumour suppressors p53 and Rb require specific 
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protein to protein interactions to mediate their respective functions. RBBP 6 protein is one of 
very few proteins known to interact with both p53 and Rb.   
In this study, the cytotoxicity assay showed that MCF-7 exhibited sensitivity to both E. 
mauritanica and K. foetidissima whilst YMB-1 cells were sensitive to E. mauritanica only 
(Figures 3.3 & 3.4). The flow cytometric assay further indicated that death was induced by an 
apoptotic pathway (Figures 4.3 & 4.4). With the high rate of p53 and Rb mutations that have 
been shown to occur in cancer and the fundamental role these genes play in tumour suppression, 
we thus aimed to investigate if the herbal extracts could restore or upregulate the levels of p53 
and reduce expression levels of RBBP6 in MCF-7 breast cancer cells thereby increasing 
apoptosis. This was done by means of real-time PCR, which can accurately measure changes in 
gene expression levels. 
Real-Time PCR is a highly sensitive and powerful method used for quantitating small changes in 
gene expression. Its accuracy and the rapid quantification of results make it the ideal method of 
nucleic acid quantification (Klein 2002; Pfaffl 2001). Real-Time PCR was employed to (i) 
investigate the expression levels of the above mentioned tumour suppressors: p53 and RBBP6 in 
MCF-7 breast cancer cells and (ii) to investigate if the herbal extracts which were inducing 
apoptosis to these cells were having any effect on the expression levels of these tumour 
suprressors.   
5.2 Primer efficiency assessment using standard curves 
To answer the above questions, real-time PCR specific primers were designed using NCBI for 
collection of gene sequences, primer3plus for designing primers and NCBI Blast for ensuring 
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that the primers were specific to our target gene and did not amplify non-target sequences. Prior 
to real-time PCR, the primers were checked for efficiency by normal PCR.  
The designed primer sequences were as follows: 
GADPH: Forward – 5/ -GAG TCA ACG GAT TTG GTC GT- 3/ 
                 Reverse – 5/ -TTG ATT TTG GAG GGA TCT CG- 3/ 
                 Product Size:   238 bp 
β-actin:    Forward – 5/-AGA GCT ACG AGC TGC CTG AC- 3/ 
                 Reverse – 5/ –AGC ACT GTG TTG GCG TAC AG- 3/  
                 Product Size:   184 bp 
RBBP6:   Forward – 5/ –CAG CGA CGA CTA AAA GAA GAG TCT- 3/ 
                 Reverse – 5/ – GGT AAT TGC GGC TCT TGC CT- 3/ 
                 Product Size:  199 bp 
p53:          Forward – 5/ -GTT CCG AGA GCT GAA TGA GG- 3/ 
                  Reverse – 5/ -TGA GTC AGG CCC TTC TGT CT -3/ 
                 Product Size:  157 bp 
Efficiency of the primers was assessed by preparing standard curves from 10 fold serial dilutions 
(undiluted, 1:10, 1:100, 1:1000 and 1:10000) of MCF-7 cDNA. Beta-actin and GADPH are 
representative of the housekeeping genes used to validate efficacy of the real-time PCR 
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experiments. The real-time PCR cocktail was prepared as explained in appendix A4 and the real-
time PCR running parameters are explained in Table 2.1. 
                
                 
                   
                             
Figure 5.1: Standard curves for Beta-actin (A) and GADPH (B) primers which served as 
housekeeping genes.  
The amplification efficiencies of the slopes were 1.834 and 1.941, respectively. n= 2 
A 
B 
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Figure 5.2: Standard curves for the tumour suppressors RBBP6 (A) and p53 (B) primers. 
The amplification efficiencies of the slopes were 1.981 and 1.932, respectively. n= 2 
 
 
 
A 
B 
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5.3 Relative quantitative real-time polymerase chain reaction  
Relative quantification, which is based on the relative expression of the target gene versus that of 
a housekeeping gene, was the preferred mode of quantification for this study. Housekeeping 
genes are constitutively expressed in all nucleated cells since they are required for basic cell 
survival. Their mRNA is considered stable even under changing experimental conditions (Pfaffl 
2001). Housekeeping genes such as glyceraldehyde-3-phosphate dehydrogenase (GADPH), 
actins, tubulins, cyclophilin, 18S rRNA and 28S rRNA are an absolute prerequisite for use in 
real-time RT-PCR experiments to ensure accurate normalisation of the experiments (Schmittgen 
and Zakrajsek 2000). For this study, mRNA expression levels were normalised to the levels of 
GADPH and β-actin transcripts, which served as our housekeeping or reference genes. 
One-step real-time PCR requires a separate step of reverse transcription of mRNA to cDNA 
before running RT-PCR. This method is ideal in that the starting amount of cDNA can be 
equalised to ensure the difference in expression level of genes is not due to experimental error. 
The following mRNA templates were reverse transcribed as in section 2.2.3 in preparation of 
RT-PCR: 
i. Untreated MCF-7 cells 
ii. MCF-7 cells treated with K. foetidissima 
iii. MCF-7 cells treated with E. mauritanica 
iv. Standard ( Prepared from untreated cells at one of the concentrations correlating with one 
of the points or concentrations on the standard curve)   
v. Negative control (-ve) 
vi. No template control  (NTC) 
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To validate if the selected housekeeping genes were the best possible for normalisation of these 
experiments, we had to test if they were stably expressed under changing experimental systems. 
Real-time PCR amplification curves were constructed using (1) GADPH and (2) β-actin primers. 
Each run comprised of (i), (ii) and (iii), all experiments were conducted in duplicates with (iv), 
(v) and (vi) also included. 
 
 
 
 
 
 
 
 
55 
 
5.4 Results and discussion 
                      
                
 
Figure 5.3: Amplification curves for the housekeeping genes.  
A) GADPH and B) β-actin primers. The curves were constructed using cDNA from a) untreated 
MCF-7 cells, K. foetidissima and E. mauritanica treated cells. All experiments were performed 
in duplicates b) A standard, c) NTC and -ve control were included.  
A 
B 
a 
b
, 
b
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c 
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, 
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Figure 5.4:  Amplification curves for RBBP6 expression. 
a) untreated MCF-7 cells, K. foetidissima and E. mauritanica treated MCF-7 cells b) A standard, 
c) NTC and -ve control were included.  
 
Figure 5.5: RT-PCR products resolved on a gel following RBBP6 amplification.  
M represents the molecular weight marker (MassRuler DNA Ladder Mix, Fermentas), U 
represents untreated MCF-7 cells, K.F and E.M represent K. foetidissima and E. mauritanica 
treated MCF-7 cells, respectively. 
M      U     K.F    E.M 
a 
b 
c 
~200bp 
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Figure 5.6: Amplification curves for p53 expression.  
a) Untreated MCF-7 cells, K. foetidissima and E. mauritanica treated MCF-7 cells. b) A 
standard, c) NTC and -ve control were included. 
 
Figure 5.7: RT-PCR products resolved on a gel following p53 amplification.  
M represents the molecular weight marker, U represents untreated  MCF-7 cells, K.F and E.M 
represent K. foetidissima and E. mauritanica treated MCF-7 cells, respectively. 
M     U    K.F   E.M 
a 
b 
c 
~200bp 
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There are currently a number of mathematical models used to analyse real-time PCR data. A 
fairly new and simple method by Pfaffl (2001) was used since it seems to provide the most 
accurate data quantification. This method compares the ratio of the target gene to that of the 
reference (housekeeping) gene. The relative expression ratio of an unknown target is computed 
based on its real-time PCR efficiencies, the crossing point difference of the unknown target 
versus that of the control in comparison to that of the control (Pfaffl 2001).  
 
Where: 
Etarget = real time PCR efficiency of target gene                                                                                                                                              
Eref = real time PCR efficiency of reference gene 
ΔCPtarget = Deviation in crossing point of control - crossing point of target gene 
ΔCPref = Deviation in crossing point of control - crossing point of reference gene 
 
 
 
 
 
Relative   expression  =  (Etarget) 
ΔCPtarget (control – sample) 
 
     (Eref) 
ΔCPref (control – sample)        
 
(Pfaffl  2001)
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P53: β-actin 
1. Untreated - 1.05 
2. K. foetidissima - 0.75 
3. E. mauritanica - 0.79 
 
Figure 5.8: Relative expression of p53 versus that of β-actin housekeeping gene. 
P53 expression levels for 1. Untreated MCF-7 cells, 2. K. foetidissima and 3. E. mauritanica 
treated cells.n=2. 
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P53: GADPH 
1. Untreated – 0.99 
2. K. foetidissima - 0.84 
3. E. mauritanica - 0.79 
Figure 5.9: Relative expression of p53 versus that of GADPH housekeeping gene.  
P53 expression levels for 1. Untreated MCF-7 cells, 2. K. foetidissima and 3. E. mauritanica 
treated cells. n=2.
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RBBP6: β-actin 
1. Untreated – 1.08 
2. K. foetidissima - 0.86 
3. E. mauritanica - 0.79 
Figure 5.10: Relative expression of RBBP6 versus that of β-actin housekeeping gene. 
RBBP6 expression levels for 1. Untreated MCF-7 cells, 2. K. foetidissima and 3. E. mauritanica 
treated cells. n=2. 
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RBBP6: GADPH 
1. Untreated – 1.02 
2. K. foetidissima - 0.97 
3. E. mauritanica - 0.79 
Figure 5.11: Relative expression of RBBP6 versus that of GADPH housekeeping gene. 
RBBP6 expression levels for 1. Untreated MCF-7 cells, 2. K. foetidissima and 3. E. mauritanica 
treated cells. n=2 
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Relative quantitative RT-PCR revealed that the levels of the RBBP6 transcript following 
normalisation with β-actin were 1.08 in the untreated MCF-7 cells (Figure 5.10). Treatment with 
K. foetidissima slightly reduced expression levels to 0.86 and with E. mauritanica it was reduced 
to 0.79. Following normalisation with GADPH, the RBBP6 levels seemed to have been slightly 
reduced from 1.02 to 0.97 whilst treatment with E. mauritanica led to a slightly higher reduction 
of 0.79 (Figure 5.11). 
The relative expression levels of p53 in MCF-7 cells following normalisation with β-actin were 
1.05 before treatment (Figure 5.8). Treatment with K. foetidissima slightly reduced expression 
levels to 0.75 and with E. mauritanica it was reduced to 0.79. Following normalisation with 
GADPH, relative expression of p53 in the untreated cells was 0.99, it was slightly reduced to 
0.84 following treatment with K. foetidissima. Treatment with E. mauritanica yielded a slight 
reduction of 0.79 (Figure 5.9). The herbal extracts K. foetidissima and E. mauritanica exhibit 
minimal effect on the expression levels of the tumour suppressors p53 and RBBP6. Both extracts 
caused a slight reduction in the expression of both genes.  
In summary, the crude extracts of E. mauritanica and K. foetidissima induced apoptosis on 
MCF-7 cells, but, RT-PCR analysis indicated that their mode of action is not by upregulating 
p53 or downregulating RBBP6. Since apoptosis is controlled by such a huge network of genes 
and signalling molecules, it is possible that these plant extracts control other components of the 
apoptotic pathway. Further research that incorporates isolation and identification of the active 
compounds would be required to better understand their molecular mechanism and the pathway 
components they affect.  
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CHAPTER 6 GENERAL DISCUSSION AND CONCLUSION 
6.1 General discussion 
Historically, plants, herbs and spices were a folkloric source of medicinal agents, and as modern 
medicine expanded, many useful drugs were developed from lead compounds discovered from 
medicinal plants. This approach has provided leads against various pharmacological targets, 
including cancer, malaria and pain, and remains an important route to new pharmaceuticals 
(Essack 2006). Recent advances in cytotoxic and phytochemical screening have provided 
scientists with insight into the bioactive properties of medicinal plants, which has led to the 
development of new medicines. In this study, Kedrostis foetidissima, Euphorbia mauritanica and 
Elytropappus rhinocerotis plants which are indigenous to South Africa and its neighbouring 
countries were screened for their possible antiproliferative and/or pro-apoptotic effect on two 
breast cancer cell lines: MCF-7 and YMB-1. 
 
MTT assay was used to measure significant variations in the inhibitory activity of the 3 plant 
extracts on breast cancer cell lines. The best thing about MTT is that it does not have limitations 
and one can test as many times as possible. It was used to measure IC50, the concentration of the 
plant extract that induces 50% cell death on the breast cell lines. Untreated cells were included as 
a control and cells treated with staurospaurine as a positive control. Little to no cell cytotoxicity 
was observed when Elytropappus rhinocerotis was used in these two cell lines. From our results 
as described in Chapter 3 (Figures 3.3 & 3.4), we observed interesting results with Kedrostis 
foetidissima being able to induce up to 48% and 53% cell death in MCF-7 and YMB-1 cells 
respectively, at a concentration of 100 µg/ml. Whereas Euphorbia mauritanica induced up to 
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40% cell death in MCF-7 but insignificant cell death of less than 20% in YMB-1 could be 
observed. In this case, only MCF-7 showed to be a cell line that can be used to assess the growth 
inhibition potential of Euphorbia mauritanica. The results obtained especially for E. mauritanica 
treatments, are similar to those observed by Kummalue et al. (2011) who compared inhibition of 
cell growth by Sapindusrarax water extract on two lung cancer cell lines and a breast cancer cell 
line; they also observed a significant growth inhibition in a dosage dependent manner, but only 
in the A549 cell line, and no significant growth inhibition was observed in the other two cell 
lines. These results therefore suggest that this plant extract might be cell line specific and cancer 
type dependent. 
 
After the confirmation that the two plant extracts indeed managed to induce significant cell death 
in the two breast cancer cell lines tested, we had to verify if the type of cell death induced was 
due to apoptosis, which is genetically controlled or if it was due to necrosis. One way of 
verifying this was by the use of flow-cytometry staining which uses both the propidium iodide 
and FITC. Propidium iodide stains cells in their late apoptotic stages as well as G1 cell cycle 
arrest and FITC stains cells in the early stages of apoptosis. Kedrostis foetidissima was then 
further assessed for possible pro-apoptotic activity using flow cytometer on MCF-7 and YMB-1 
cells, whilst E. mauritanica was assessed on MCF-7 cells. Similarly to the cytotoxicity assays, 
staurospaurine was used as the positive control whilst cells that were not treated with anything 
but media were used as the control. 
The results confirmed our earlier findings that indeed cell death had been induced following 
treatment with the two plant extracts, and that it was as a result of apoptosis. YMB-1 and MCF-7 
cells treated with K. foetidissima at a concentration of 100 µg/ml demonstrated a 40% and 30% 
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phosphatidylserine residue externalization, respectively; whilst MCF-7 cells treated with E. 
mauritanica demonstrated a 40% phosphatidylserine residue externalization, which is an 
indication of induced apoptosis. Staurospaurine induced just over 40% apoptosis in both cell 
lines. This demonstrated that treatment of MCF-7 cells with K. foetidissima and E. mauritanica 
and of YMB-1 cells with K. foetidissima resulted in a significant induction of apoptosis, while 
showing relatively no significant toxicity to the cells in the form of necrosis. 
Research into the development of novel small-molecule plant-derived extracts and compounds, 
which may prevent carcinogenesis, curtail its progression, or even cure the disease is still at the 
forefront of cancer therapeutics (D’Archivio et al. 2007). With studies by Creemers et al. (1994) 
showing compounds such as irinotecan and topotecan derived from Nyssacea Camptotheca 
accuminata as the main inducers of apoptosis against colorectal and ovarian cancer. Kedrostis 
foetidissima, which we found to be the most potent of the plant extracts tested, has been found to 
contain cucurbitacins B, D, E, I, J ,K and L by Konopa et al. (1974). They further went on to 
show that K. foetidissima exhibits high cytotoxicity to Hela and KB human (Konopa et al. 1974), 
however the synergistic activity of these cucurbitacins need to be studied further to understand 
their exact activities on the different cancer cell lines. 
On the other hand, E. mauritanica belongs to Euphorbiaceae family, whose extracts include 
methyl esters, their derivatives and diterpene polyesters. Other compounds that have been 
discovered include alkaloids, phenolic compounds, cyanogenic glucosides and glucosinolates 
which have been identified as players in the induction of apoptosis in some cells (Rizk 1987). 
This study clearly shows promising results for this plant extract; however, further studies that 
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entail isolation and research into the biological activities of the active compounds from the plant 
E. mauritanica would provide better insight. 
As with all potential anti-tumour agents, it is crucial to understand the molecular mechanism 
underlying their apoptotic activities. In this study, we concentrated on the two genes RBBP6 and 
p53. The involvement of p53 and apoptosis in the cucurbitacins-mediated effect has been studied 
in various cancer cells (Miro 1995; Rios et al. 2005). In response to various cellular stresses, p53 
is phosphorylated on NH2-terminal residues. In particular, the phosphorylation of Ser 15 affects 
the interaction with the negative regulator MDM2 oncoprotein and enhances contribution to the 
stabilization of p53 (Chen et al. 2008; Suzuki et al. 2007). Phosphorylation of p53 is mediated 
by phosphoinositide-3-kinase (PI3K)-related proteins, including Ataxia telangiectasia-mutated 
(ATM), ATM- and Rad3- related kinase (ATR) and DNA-dependent protein kinases (DNA-
PKs).  
While p53 plays numerous roles in the cell, our experiments focused on distinguishing whether 
K. foetidissima and E. mauritanica-induced apoptosis was p53 dependent or independent. On the 
other hand RBBP6 is a negative regulator of p53 that results in the ubiquitination of p53 thereby 
leading to cell proliferation (Motadi et al. 2011). Kedrostis foetidissima and Euphorbia 
mauritanica treated cells revealed that p53 was not significantly increased (Tables 5.1 and 5.2) 
following treatment with the extracts. Similarly, RBBP6 levels did not differ among the K. 
foetidissima and E. mauritanica treated cells with less than 1/16 fold decrease (Tables 5.3 and 
5.4). The biological activities of these plants have not been studied in depth, however, several 
studies have looked at the molecular mechanisms of different curcubitacins and Euphorbia 
species on different cancer cells. Lee et al. (2010) reviewed the molecular mechanism of 
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cucurbitacins and gathered that they target different oncogenic signalling pathways that have 
been implicated in cancer such as the MAPK, JAK-STAT and the Akt-PKB pathways. The JAK-
STAT pathway induces Signal Transducers and Activators of Transcription (STATs) and Janus-
Kinases (JAKs). Cucurbitacin B was found to inhibit downstream phosphorylation of some 
STATs and JAKs in pancreatic tumours, thereby inhibiting this pathway affecting several of its 
downstream targets involved in apoptosis such as p53 and Bcl-2 (Lee et al. 2010). Escandell et 
al. 2008 investigated cucurbitacin R and cucurbitacin I on HCT116 cells harbouring a Ras 
mutant and found that they induced expression of p53 and p21. They further reported that 
cucurbitacin R resulted in p53 protein overexpression and Bcl-2 downregulation following 8, 12 
and 18 hour treatments in RAW 264.7 macrophages.  
One of the most prominent compounds that has been identified in Euphorbia species are 
jatrophane esters, which belong to Euphorbia semiperfoliata (Cragg and Newman 2005). This 
was discovered following research on chemotypes of the drug taxol (explained in section 1.7.1), 
which exhibited poor water solubility and side effects. Miglietta et al. (2002) looked at the effect 
of these jatrophane polyesters (250 nM) on MCF-7 cells over a period of 16 hours and observed 
that they highly induced expression of p53 and also abrogates Bcl-2 probably through the Raf-1 
mediated signaling pathway. These results, however, are contradictory to our observations where 
expression of p53 was slightly reduced. This could be attributed to the diversity of compounds 
which have been identified from Euphorbia species. Hence future studies will require further 
isolation of the active compounds within E. mauritanica and molecular mechanism 
investigations. 
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In summary, the crude extracts of K. foetidissima induced apoptosis in both MCF-7 and YMB- 1 
cells whilst those of E. mauritanica induced apoptosis in MCF-7. RT-PCR indicated that their 
mode of action is in a p53 independent manner. Since apoptosis is controlled by such a huge 
network of genes and signalling molecules, it is possible that these plant extracts control other 
components of the apoptotic pathway. Further research that incorporates isolation and 
identification of the active compounds would be required to better understand their molecular 
mechanism and the molecular pathway that follows this apoptosis induction.  
6.2 Conclusion and future perspectives 
Inducers of apoptosis are considered good agents in anti-cancer therapeutics. Small molecules 
and natural plant extracts have recently attracted attention to modern medical science research 
with their non-lethal activity. In this study, crude extracts of three indigenous South African 
plants were screened for their antiproliferative activity against two breast cancer cell lines: MCF-
7 and YMB-1. This study revealed that not only did K. foetidissima and E. mauritanica plant 
extracts demonstrate antiproliferative activity to the breast cancer cells, but they induced cell 
death by apoptosis, rendering them good agents in anticancer drug discoveries.  
It could not be determined in this research which components of the apoptotic pathway are being 
regulated. Hence, further research which includes isolation and characterisation of the active 
compounds present in these plants is required. Further research into the molecular targets of the 
isolated active compounds would also provide better insight on the molecular mechanisms of 
action of these plant extracts.   
In conclusion, this study has further suggested the importance of using or targeting traditional 
plant extracts as potential therapy against several cancers and other illnesses. However, we 
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should continue to approach this with caution as most plant extracts turn to be unsuccessful once 
several secondary metabolites are separated.  
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APPENDIX A 
 
            
        Figure A.1: Cytotoxicity of Elytropappus Rhinocerotis on MCF-7 breast cancer cells. 
            
Figure A.2 Cytotoxicity of Elytropappus Rhinocerotis on YMB-1 breast cancer cells.  
 (Figure A1 and A2) Cells were treated for 24 hours at increasing concentrations of 10, 30, 50 
and 100 µg/ml using the plant aqueous extracts. A staurospaurine control was included. 25 nM-S 
represents the positive control, staurospaurine, at a concentration of 25 nM. n = 5, p < 0.05 
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APPENDIX B 
 
Table B.1: RNA extraction protocol 
Step 1  Cells were harvested(10
6
) and resuspended in 200 µl PBS  
Step 2 400 µl Lysis/Binding buffer was added, contents were mixed well, then added to 
upper reservoir of the High Pure Filter Tube assembly 
Step 3 These were centrifuged for 15seconds at 8000 x g, flowthrough was discarded. 
Step 4 Each sample was incubated with a mixture of 90 μl DNase I Incubation Buffer 
and 10 μl DNase I for 15 minutes at 25°C. 
Step 5 Wash Buffer 1(500 μl) was added to each sample, these were centrifuged for 
15seconds at 8000 x g. Flowthrough was discarded. 
Step 6 Wash Buffer II (500 μl) was added to each sample, these were centrifuged for 
15seconds at 8000 x g. Flowthrough was discarded. 
Step 7 Wash Buffer II (200 μl) was added to each sample, these were centrifuged for 2 
minutes at 13000 x g. Flowthrough was discarded through collection tube. 
Step 8 50 μl of Elution Buffer was added then centrifuged for 1minute at 8000 x g 
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Table B.2: The cocktail for cDNA synthesis  
Reagent  Volume 
10X reaction buffer 2.0 µl 
25 mM Magnesium Chloride  3.0 µl 
Deoxyribonucleotide mix 2.0 µl 
Specific primers 2.5 µl 
RNase inhibitor 1.0 µl 
AMV reverse transcriptase 1.0 µl 
sdH2O 7.5 µl 
RNA sample 1.0 µl 
Total volume 20 µl 
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Table B.3: Reverse transcription conditions 
Step Temperature Time (minutes) 
Step 1 25 °C 10  
Step 2  42 °C 60 
Step 3 70 °C 15 
Step 4 4 °C ∞ 
 
 
Table B.4: Real-time PCR cocktail  
Reagent Volume 
SyBr Green 10 µl 
Forward primer 1 µl 
Reverse primer 1 µl 
H2O 7 µl 
1µl of the respective cDNAs were added lastly to the capillaries. 
Total 20 µl 
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APPENDIX C 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C.1: Melting curves for GADPH 
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APPENDIX D  
 
Figure D.1: Cytotoxicity of Euphorbia mauritanica and Kedrostis hirtella extracts.  
Cells were treated with herbal extracts at a concentration of 5 µg/ml on MRC5 primary human 
fibroblast cells, minimal growth inhibition was observed at low concentrations (Thafeni 
unpublished). 
 
Figure D.2 : Cytotoxicity of Euphorbia mauritanica and Kedrostis hirtella extracts.  
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Cells were treated with herbal extracts at a concentration of 10 µg/ml on MRC5 primary human 
fibroblast cells, minimal growth inhibition was observed at minimal concentrations (Thafeni 
unpublished). 
.  
 
